Anthrax infection is initiated by the inhalation, ingestion, or cutaneous contact with Bacillus anthracis endospores.
B.
anthracis produces three polypeptides that comprise the anthrax toxin: protective antigen (PA), lethal factor (LF), and edema factor (EF).
PA binds to two related proteins on the cell surface; these are termed tumor epithelial marker 8 (TEM8)/anthrax toxin receptor (ATR) and capillary morphogenesis protein 2 (CMG2), although it is still unclear which is physiologically relevant.
Following PA binding to its receptor, PA is cleaved into two fragments by a furin-like protease.
The bound fragment binds both LF and EF; the resulting complex is then endocytosed which allows the translocation of LF and EF into the cytoplasm.
EF is a calmodulin and Ca++-dependent adenylate cyclase responsible for the edema seen in the disease.
It is thought to benefit the B.
anthracis bacteria by inhibiting cells of the host immune system.
Applications:Suitable for use in ELISA and Western Blot.
Other applications not tested.
Recommended Dilution:Western Blot: 1:2000Optimal dilutions to be determined by the researcher.
Antitoxin Titer:1:1850 in a 2mg/ml solution in an ELISA assay.
Storage and Stability:Lyophilized powder may be stored at -20°C.
Stable for 12 months after receipt at -20°C.
Reconstitute with sterile ddH2O.
Aliquot to avoid repeated freezing and thawing.
Store at -20°C.
Reconstituted product is stable for 12 months at -20°C.
For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
